News from Glycobond

Glycobond receives funding from the Horizon 2020 SME instrument of the European Commission.

The funding will be used for planning of further clinical validation and commercial launch of HepaCheC in Europe. The assay, an in vitro diagnostic device, aids in diagnosis of primary liver cancer, the third deadliest cancer worldwide.

The application received high scores in the evaluation from the European Commission.